Chamika Hawkins-Taylor is an assistant professor in the Department of Pharmacy Practice at Xavier University of Louisiana. Her research focuses on the factors influencing the distribution of chronic diseases in unders, treatment and outcomes of underserved, minority populations with a focus of social determinants of health. She has experience in research on chronic disease management and is exploring medication adherence, drug misuse and abuse, and social contributors to population health. Current projects focus on opioid misuse, palliative care, and chronic disease management in elderly, black populations.

Education:

PhD-University of Minnesota 2010

MHA-University of Southern California 2005

BA-University of California, Davis 1998 

Clinical Specialties: (as applies)

N/A

Teaching Areas: (as applies)

Public Health (Social Epidemiology, Health Literacy, Health Disparities, Health Policy)

Pharmacy Management 

Research Interests: (as applies)

Dr. Hawkins-Taylor’s research is focused on chronic disease epidemiology, treatment and outcomes in underserved, minority populations with a focus of social determinants of health. In shaping her research agenda, She has served in Co-PI and Co-Investigator roles for projects sponsored by PCORI and CDC focused on multiple sclerosis, cancer related palliative care, cancer survivorship and medication therapy management. She is presently the Project Director on a HRSA-sponsored planning grant to combat opioid abuse in rural areas. She also serve as public health expert on two Opioid-focused grants funded by SAMHSA and USDA, responsible for the development of education resources for dissemination to farming and ranching communities within South Dakota. Her scholarship portfolio to date represents a dedication and growing expertise in chronic disease management and special populations where there are apparent differences in the etiology and manifestation of disease and therapeutic outcomes.  Whether those knowledge gaps are a result of the intersection between poverty and health care access or other social risk factors, it is my long term goal to contribute to the work of disparities, many of which result in a difference in length of life years just within a short geographic difference of a few miles.

Selected Peer-Reviewed Publications

Pinto, S, Dickinson, A, Middendorf, A, Hawkins-Taylor, C. 2019. Pharmacology Focus: Breaking barriers to improve medication management in practice. South Dakota Medicine. 72(4):178-180.

Hawkins-Taylor, C., Carson, P, Anderson, D, Carlson, A. et al. 2019. Making the case for optimal use of survivorship care plans. Oncology Nursing Forum, 46(5):585-594.

Sage, S, Hawkins-Taylor, C, Crockett, A, Balls-Berry, J. 2019. “Girl just pray…” Factors that influence breast and cervical cancer screening among black women in Rochester, MN. Journal of the National Medical Association.

Kerkvliet, J, J. Cowan, H. Wey, C. Hawkins-Taylor, P. Carson. 2018. Year Two Evaluation of the South Dakota Survivorship Program. CDC DP15-1501, Annual Report, Program Year 2.

Hawkins-Taylor, C. 2017. Differences in the manifestation of multiple sclerosis in African American patients. South Dakota Medicine, 70(8): 372-373.

Hawkins-Taylor, MB Taylor, AM Carlson. 2018. Pharmacy practice in South Dakota Correctional Systems: Discovery of an unconventional experiential practice site. Innovations in Pharmacy.9(4):1-10.

Hawkins-Taylor, C. 2017. Differences in the manifestation of multiple sclerosis in African American patients. South Dakota Medicine, 70(8): 372-373.

Mort, JR, C. Hawkins-Taylor, 2016. Disparities in Medication Use among Elder American Indians: Evidence, Causes, Implications. Chapter in: Indigenous Peoples: Perspectives, Cultural Roles and Health Care Disparities. New York. Nova Science Publishers, Inc.

Carlson, A.M, C. Hawkins-Taylor, 2015. Social Epidemiology. Chapter in Social and Behavioral Aspects of Pharmacy Practice. 6^th Edition. A. Wertheimer, N. Rickles, J. Schumer. Boston. Jones and Bartlett.

Hawkins-Taylor, C., A. M Carlson 2013.  Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil, American Health and Drug Benefit, 6(7):401-412.

S.E. Marino; S.V.S. Pakhomov; S. Han; K.L. Anderson; M. Ding; L.E. Eberly; D.W. Loring; C. Hawkins-Taylor; J.O. Rarick; I.E. Leppik; et al. 2012. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory Epilepsy and Behavior, 24(3):365-378.